Raynaud phenomenon: from GWAS to drug repurposing

The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α 2A -adrenoceptors, and suggests opportunities for drug repurposing.